nderstanding the prevalence ,risk factors, and drug responses to polycystic ovary syndrome among Indian Women.
Phase 4
Completed
- Conditions
- Health Condition 1: E898- Other postprocedural endocrine andmetabolic complications and disorders
- Registration Number
- CTRI/2018/11/016252
- Lead Sponsor
- SKIMS
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1) Women aged 18-40 years.
2) Women permanent residents of that area ( >1 year).
3) Willingness to participate in the study and sign informed consent.
4) Women who are known to have PCOS not on treatment.
Exclusion Criteria
1) Pregnant or lactating women and those with cognitive and/or physical limitations that prevented them from answering the questionnaire will be excluded from the study.
2) History of drug intake such as steroids, androgen, oral contraceptives, anti-epileptics or drugs known to interfere in glucose and lipid metabolism.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method a)Estimation of national prevalence, phenotypic variations and risk factors of PCOS in community. <br/ ><br>b)Quantitation of comorbidities among known cases of PCOS <br/ ><br>c)Comparison of the variation in efficacy of standard therapeutics modalities for metabolic dysfunction in PCOS women <br/ ><br>Timepoint: Baseline and follow up at the interval of 3 month and 6 month
- Secondary Outcome Measures
Name Time Method a)Identification of prenatal/pre-pubertal factors including low birth weight, sexual precocity, pre-pubertal obesity, familial aggregation, maternal PCOS, GDM, antiepileptic drug, etc. contributing in the causation of PCOS. <br/ ><br>b)Assessment of knowledge and management practices among service providers in public health sector on PCOSTimepoint: Baseline,